Type
Internal restructuring
Country
Germany
Region
Nordrhein-Westfalen; Düsseldorf; Wuppertal
Location of affected unit(s)
Wuppertal
Sector
Manufacturing
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations

440 jobs
Number of planned job losses
Job loss
Announcement Date
2 December 2004
Employment effect (start)
Foreseen end date

Description

Bayer HealthCare (BHC) will bring the Research and Development departments in line with the Pharmaceuticals Division’s strategy of concentrating on specific therapeutic segments and increasing regional differentiation. In the future, research at Bayer HealthCare will concentrate on the therapeutic fields of cancer and cardiovascular risk management including diabetes at its sites in West Haven, Connecticut, and Wuppertal, Germany. It will include reductions to global personnel in Research & Development and Production, affecting some 560 positions. Approximately 110 jobs in the United States and around 440 jobs in Germany will be affected by the restructuring measures. Bayer’s Employment Pact with employees means the company may not dismiss staff in Germany for economic reasons before the end of 2007. Bayer plans to reduce personnel in a way that will minimize social hardship and will seek to find individual solutions for the staff affected.


Sources

  • 2 December 2004: Financial Times Deutschland
  • 2 December 2004: Bayer - Press release
  • 2 December 2004: Frankfurter Allgemeine Zeitung

Citation

Eurofound (2004), Bayer HealthCare (BHC), Internal restructuring in Germany, factsheet number 60884, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/60884.